These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1241 related items for PubMed ID: 31539077

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q.
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [Abstract] [Full Text] [Related]

  • 5. Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.
    Pan YH, Zhang JX, Chen X, Liu F, Cao JZ, Chen Y, Chen W, Luo JH.
    Front Immunol; 2021 Apr; 12():643282. PubMed ID: 34421886
    [Abstract] [Full Text] [Related]

  • 6. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X, Xu H, Xue Q, Wen R, Jiao W, Tian K.
    Mol Med; 2021 Oct 07; 27(1):126. PubMed ID: 34620079
    [Abstract] [Full Text] [Related]

  • 7. Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.
    Zhang K, Hong X, Song Z, Xu Y, Li C, Wang G, Zhang Y, Zhao X, Zhao Z, Zhao J, Huang M, Huang D, Qi C, Gao C, Cai S, Gu F, Hu Y, Xu C, Wang W, Lou Z, Zhang Y, Liu L.
    Clin Cancer Res; 2020 Jul 15; 26(14):3649-3661. PubMed ID: 32241817
    [Abstract] [Full Text] [Related]

  • 8. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Zhang L, Zhang T, Shang B, Li Y, Cao Z, Wang H.
    Scand J Immunol; 2021 Sep 15; 94(3):e13087. PubMed ID: 35226388
    [Abstract] [Full Text] [Related]

  • 9. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X, Wang Y, Li X, Feng G, Hu S, Bai Y.
    Front Immunol; 2021 Sep 15; 12():638763. PubMed ID: 34305884
    [Abstract] [Full Text] [Related]

  • 10. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J.
    Ann Oncol; 2018 Oct 01; 29(10):2068-2075. PubMed ID: 30165392
    [Abstract] [Full Text] [Related]

  • 11. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Treviño S, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV.
    Clin Cancer Res; 2023 Dec 01; 29(23):4958-4972. PubMed ID: 37733794
    [Abstract] [Full Text] [Related]

  • 12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 13. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM.
    JAMA Oncol; 2022 Aug 01; 8(8):1160-1168. PubMed ID: 35708671
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, Choueiri TK, Hsieh JJ, Hakimi AA, Motzer RJ.
    Lancet Oncol; 2018 Dec 01; 19(12):1688-1698. PubMed ID: 30416077
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
    Torralvo J, Friedlaender A, Achard V, Addeo A.
    Cancer Genomics Proteomics; 2019 Dec 01; 16(6):577-582. PubMed ID: 31659111
    [Abstract] [Full Text] [Related]

  • 19. Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study.
    Cao J, J Gu J, Liang Y, Wang B.
    Technol Cancer Res Treat; 2022 Dec 01; 21():15330338221138213. PubMed ID: 36524293
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.